Trade Sanofi SA - SAN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.36 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.019974% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.002248% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | EUR | ||||||||
Margin | 20% | ||||||||
Stock exchange | France | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Sanofi SA ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 94.07 |
Open* | 94.54 |
1-Year Change* | -5.38% |
Day's Range* | 94.54 - 95.76 |
52 wk Range | 76.45-105.18 |
Average Volume (10 days) | 1.32M |
Average Volume (3 months) | 35.87M |
Market Cap | 119.05B |
P/E Ratio | 14.19 |
Shares Outstanding | 1.25B |
Revenue | 46.20B |
EPS | 6.65 |
Dividend (Yield %) | 3.77479 |
Beta | 0.47 |
Next Earnings Date | Jul 28, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
May 30, 2023 | 94.07 | -1.43 | -1.50% | 95.50 | 96.37 | 93.84 |
May 29, 2023 | 98.66 | 0.52 | 0.53% | 98.14 | 99.14 | 98.14 |
May 26, 2023 | 99.17 | 0.77 | 0.78% | 98.40 | 99.36 | 97.94 |
May 25, 2023 | 98.30 | -1.56 | -1.56% | 99.86 | 100.60 | 98.20 |
May 24, 2023 | 100.56 | 0.14 | 0.14% | 100.42 | 101.42 | 100.18 |
May 23, 2023 | 100.72 | 0.92 | 0.92% | 99.80 | 100.90 | 99.48 |
May 22, 2023 | 100.08 | -1.26 | -1.24% | 101.34 | 101.94 | 99.88 |
May 19, 2023 | 101.42 | 1.79 | 1.80% | 99.63 | 101.88 | 99.63 |
May 18, 2023 | 99.64 | 0.65 | 0.66% | 98.99 | 99.86 | 98.99 |
May 17, 2023 | 98.60 | -1.32 | -1.32% | 99.92 | 99.96 | 98.41 |
May 16, 2023 | 100.10 | 0.99 | 1.00% | 99.11 | 100.20 | 99.08 |
May 15, 2023 | 99.54 | -0.06 | -0.06% | 99.60 | 100.44 | 99.28 |
May 12, 2023 | 99.04 | -0.27 | -0.27% | 99.31 | 100.28 | 98.88 |
May 11, 2023 | 98.97 | -0.38 | -0.38% | 99.35 | 99.81 | 98.44 |
May 10, 2023 | 98.29 | -1.44 | -1.44% | 99.73 | 99.86 | 98.04 |
May 9, 2023 | 100.48 | 0.28 | 0.28% | 100.20 | 100.80 | 99.71 |
May 8, 2023 | 100.00 | -0.68 | -0.68% | 100.68 | 100.94 | 99.71 |
May 5, 2023 | 101.38 | 2.20 | 2.22% | 99.18 | 101.38 | 99.05 |
May 4, 2023 | 99.10 | 0.97 | 0.99% | 98.13 | 99.53 | 97.50 |
May 3, 2023 | 97.70 | 0.86 | 0.89% | 96.84 | 97.72 | 96.21 |
Sanofi SA Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, June 29, 2023 | ||
Time (UTC) 12:00 | Country FR
| Event Sanofi SA Vaccines Investor Event Sanofi SA Vaccines Investor EventForecast -Previous - |
Friday, October 27, 2023 | ||
Time (UTC) 05:30 | Country FR
| Event Q3 2023 Sanofi SA Earnings Release Q3 2023 Sanofi SA Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 45389 | 39175 | 37369 | 37631 | 35677 |
Revenue | 45389 | 39175 | 37369 | 37631 | 35677 |
Cost of Revenue, Total | 13695 | 12255 | 12159 | 11979 | 11435 |
Gross Profit | 31694 | 26920 | 25210 | 25652 | 24242 |
Total Operating Expense | 34733 | 31049 | 23256 | 34580 | 31001 |
Selling/General/Admin. Expenses, Total | 10410 | 9457 | 9304 | 9777 | 9772 |
Research & Development | 6705 | 5689 | 5528 | 6017 | 5890 |
Depreciation / Amortization | 2140 | 1681 | 1774 | 2262 | 2264 |
Unusual Expense (Income) | -581 | 235 | 777 | 3966 | 1696 |
Other Operating Expenses, Total | 2391 | 1728 | 1220 | 817 | 61 |
Operating Income | 10656 | 8126 | 14113 | 3051 | 4676 |
Interest Income (Expense), Net Non-Operating | -167 | -289 | -263 | -210 | -273 |
Other, Net | -67 | -39 | -72 | -89 | 2 |
Net Income Before Taxes | 10422 | 7798 | 13778 | 2752 | 4405 |
Net Income After Taxes | 8416 | 6240 | 11971 | 2631 | 3924 |
Minority Interest | -113 | -56 | -36 | -31 | -104 |
Equity In Affiliates | 68 | 39 | 359 | 255 | 499 |
Net Income Before Extra. Items | 8371 | 6223 | 12294 | 2855 | 4319 |
Total Extraordinary Items | 0 | 0 | -101 | -13 | |
Net Income | 8371 | 6223 | 12294 | 2754 | 4306 |
Income Available to Common Excl. Extra. Items | 8371 | 6223 | 12294 | 2855 | 4319 |
Income Available to Common Incl. Extra. Items | 8371 | 6223 | 12294 | 2754 | 4306 |
Dilution Adjustment | |||||
Diluted Net Income | 8371 | 6223 | 12294 | 2754 | 4306 |
Diluted Weighted Average Shares | 1256.9 | 1257.9 | 1260.1 | 1257.1 | 1255.2 |
Diluted EPS Excluding Extraordinary Items | 6.66004 | 4.94713 | 9.75637 | 2.2711 | 3.44089 |
Dividends per Share - Common Stock Primary Issue | 3.56 | 3.31263 | 3.2 | 3.15 | 3.07 |
Diluted Normalized EPS | 6.28676 | 5.09663 | 10.2921 | 5.28727 | 4.64452 |
Interest Expense (Income) - Net Operating | -27 | 4 | -7506 | -238 | -117 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total revenue | 10863 | 24594 | 13138 | 20795 | 10053 |
Revenue | 10863 | 24594 | 13138 | 20795 | 10053 |
Cost of Revenue, Total | 3079 | 7565 | 3831 | 6130 | 2880 |
Gross Profit | 7784 | 17029 | 9307 | 14665 | 7173 |
Total Operating Expense | 8400 | 17767 | 10414 | 16966 | 7656 |
Selling/General/Admin. Expenses, Total | 2607 | 5539 | 2644 | 4953 | 2379 |
Research & Development | 1563 | 3559 | 1736 | 3147 | 1489 |
Depreciation / Amortization | 489 | 1143 | 460 | 910 | 449 |
Unusual Expense (Income) | 343 | 231 | 1955 | 1021 | 198 |
Other Operating Expenses, Total | 304 | -226 | -180 | 788 | 265 |
Operating Income | 2463 | 6827 | 2724 | 3829 | 2397 |
Interest Income (Expense), Net Non-Operating | -7 | -62 | -51 | -135 | -78 |
Net Income Before Taxes | 2456 | 6748 | 2673 | 3674 | 2319 |
Net Income After Taxes | 1997 | 5237 | 2072 | 3179 | 1987 |
Minority Interest | -14 | -60 | -3 | -53 | -8 |
Equity In Affiliates | 12 | 10 | 7 | 58 | 30 |
Net Income Before Extra. Items | 1995 | 5187 | 2076 | 3184 | 2009 |
Net Income | 1995 | 5187 | 2076 | 3184 | 2009 |
Income Available to Common Excl. Extra. Items | 1995 | 5187 | 2076 | 3184 | 2009 |
Income Available to Common Incl. Extra. Items | 1995 | 5187 | 2076 | 3184 | 2009 |
Diluted Net Income | 1995 | 5187 | 2076 | 3184 | 2009 |
Diluted Weighted Average Shares | 1249.3 | 1258.5 | 1253.5 | 1255.3 | 1249.2 |
Diluted EPS Excluding Extraordinary Items | 1.59689 | 4.12157 | 1.65616 | 2.53645 | 1.60823 |
Dividends per Share - Common Stock Primary Issue | 0 | 3.56 | 0 | 0 | 0 |
Diluted Normalized EPS | 1.82014 | 4.26402 | 2.86513 | 3.24021 | 1.74404 |
Interest Expense (Income) - Net Operating | 15 | -44 | -32 | 17 | -4 |
Other, Net | -17 | -20 | |||
Total Extraordinary Items |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 34026 | 30564 | 33703 | 28611 | 24579 |
Cash and Short Term Investments | 13400 | 11152 | 14815 | 9853 | 7124 |
Cash | 1385 | 1358 | 1144 | 701 | 661 |
Cash & Equivalents | 11351 | 8740 | 12771 | 8726 | 6264 |
Short Term Investments | 664 | 1054 | 900 | 426 | 199 |
Total Receivables, Net | 10746 | 9787 | 9953 | 10083 | 9345 |
Accounts Receivable - Trade, Net | 8424 | 7568 | 7491 | 7937 | 7260 |
Total Inventory | 8960 | 8715 | 8352 | 7994 | 7477 |
Prepaid Expenses | 714 | 615 | 525 | 493 | 469 |
Other Current Assets, Total | 206 | 295 | 58 | 188 | 164 |
Total Assets | 126722 | 120242 | 114413 | 112630 | 111408 |
Property/Plant/Equipment, Total - Net | 11684 | 11976 | 10563 | 11017 | 9651 |
Property/Plant/Equipment, Total - Gross | 26796 | 27555 | 24880 | 25151 | 22697 |
Accumulated Depreciation, Total | -15112 | -15579 | -14317 | -14134 | -13046 |
Goodwill, Net | 49892 | 48056 | 44364 | 44519 | 44235 |
Intangibles, Net | 21640 | 21407 | 18341 | 16509 | 21889 |
Long Term Investments | 2765 | 2425 | 2129 | 5303 | 5550 |
Note Receivable - Long Term | 452 | 485 | 537 | 521 | 746 |
Other Long Term Assets, Total | 6263 | 5329 | 4776 | 6150 | 4758 |
Total Current Liabilities | 23964 | 21295 | 19248 | 20381 | 17376 |
Accounts Payable | 6813 | 6180 | 5295 | 5313 | 5041 |
Accrued Expenses | 2158 | 2126 | 2042 | 1978 | 1989 |
Notes Payable/Short Term Debt | 168 | 189 | 285 | 305 | 249 |
Current Port. of LT Debt/Capital Leases | 4287 | 3263 | 2714 | 4508 | 2364 |
Other Current Liabilities, Total | 10538 | 9537 | 8912 | 8277 | 7733 |
Total Liabilities | 51938 | 51561 | 51307 | 53574 | 52532 |
Total Long Term Debt | 17047 | 19015 | 20725 | 21168 | 22071 |
Long Term Debt | 15143 | 17176 | 19794 | 20181 | 22053 |
Capital Lease Obligations | 1904 | 1839 | 931 | 987 | 18 |
Deferred Income Tax | 1841 | 1617 | 1770 | 2294 | 3414 |
Minority Interest | 368 | 350 | 146 | 174 | 159 |
Other Liabilities, Total | 8718 | 9284 | 9418 | 9557 | 9512 |
Total Equity | 74784 | 68681 | 63106 | 59056 | 58876 |
Common Stock | 2522 | 2527 | 2518 | 2508 | 2495 |
Additional Paid-In Capital | 66859 | 63545 | 60511 | 52049 | 53106 |
Treasury Stock - Common | -706 | -939 | -705 | -9 | -153 |
Other Equity, Total | 6109 | 3548 | 782 | 4508 | 3428 |
Total Liabilities & Shareholders’ Equity | 126722 | 120242 | 114413 | 112630 | 111408 |
Total Common Shares Outstanding | 1252.64 | 1252.54 | 1250.69 | 1253.83 | 1245.45 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 34026 | 28360 | |||
Cash and Short Term Investments | 12736 | 6899 | |||
Cash & Equivalents | 12736 | 6899 | |||
Total Receivables, Net | 8798 | 8406 | |||
Accounts Receivable - Trade, Net | 8424 | 7868 | |||
Total Inventory | 8960 | 9366 | |||
Other Current Assets, Total | 3532 | 3689 | |||
Total Assets | 126722 | 121826 | |||
Property/Plant/Equipment, Total - Net | 11684 | 11642 | |||
Goodwill, Net | 49892 | 50555 | |||
Intangibles, Net | 21640 | 21978 | |||
Long Term Investments | 2765 | 2650 | |||
Note Receivable - Long Term | 452 | 641 | |||
Other Long Term Assets, Total | 6263 | 6000 | |||
Total Current Liabilities | 23964 | 22060 | |||
Accounts Payable | 6813 | 6558 | |||
Notes Payable/Short Term Debt | 168 | 149 | |||
Current Port. of LT Debt/Capital Leases | 4287 | 3145 | |||
Other Current Liabilities, Total | 12696 | 12208 | |||
Total Liabilities | 51938 | 50875 | |||
Total Long Term Debt | 17047 | 18134 | |||
Long Term Debt | 15143 | 16133 | |||
Capital Lease Obligations | 1904 | 2001 | |||
Deferred Income Tax | 1841 | 1550 | |||
Minority Interest | 368 | 353 | |||
Other Liabilities, Total | 8718 | 8778 | |||
Total Equity | 74784 | 70951 | |||
Common Stock | 2522 | 2531 | |||
Additional Paid-In Capital | 66859 | 555 | |||
Retained Earnings (Accumulated Deficit) | 61883 | ||||
Treasury Stock - Common | -706 | -1169 | |||
Other Equity, Total | 6109 | 7151 | |||
Total Liabilities & Shareholders’ Equity | 126722 | 121826 | |||
Total Common Shares Outstanding | 1252.64 | 1252 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 8371 | 6223 | 12294 | 2754 | 4306 |
Cash From Operating Activities | 10526 | 10522 | 7418 | 7715 | 5547 |
Cash From Operating Activities | 3420 | 3351 | 3671 | 7445 | 4279 |
Deferred Taxes | -578 | -356 | -221 | -1772 | -727 |
Non-Cash Items | 20 | -105 | -8001 | -293 | -1031 |
Cash Taxes Paid | 2452 | 1280 | 2051 | 1695 | 2058 |
Cash Interest Paid | 380 | 334 | 315 | 379 | 412 |
Changes in Working Capital | -707 | 1409 | -325 | -419 | -1280 |
Cash From Investing Activities | -2075 | -7298 | 3619 | -1029 | -12872 |
Capital Expenditures | -2201 | -2043 | -2083 | -1787 | -1977 |
Other Investing Cash Flow Items, Total | 126 | -5255 | 5702 | 758 | -10895 |
Cash From Financing Activities | -5821 | -7056 | -6485 | -4193 | 3934 |
Financing Cash Flow Items | -99 | -48 | -44 | -21 | -91 |
Total Cash Dividends Paid | -4168 | -4008 | -3937 | -3834 | -3773 |
Issuance (Retirement) of Stock, Net | -309 | -196 | -619 | 153 | -924 |
Issuance (Retirement) of Debt, Net | -1245 | -2804 | -1885 | -491 | 8722 |
Foreign Exchange Effects | 8 | 15 | -64 | 9 | 1 |
Net Change in Cash | 2638 | -3817 | 4488 | 2502 | -3390 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 8371 | 3184 | |||
Cash From Operating Activities | 10526 | 3825 | |||
Cash From Operating Activities | 3420 | 1820 | |||
Deferred Taxes | -578 | -404 | |||
Non-Cash Items | 20 | 267 | |||
Cash Taxes Paid | 2452 | 927 | |||
Cash Interest Paid | 380 | 162 | |||
Changes in Working Capital | -707 | -1042 | |||
Cash From Investing Activities | -2075 | -1459 | |||
Capital Expenditures | -2201 | -974 | |||
Other Investing Cash Flow Items, Total | 126 | -485 | |||
Cash From Financing Activities | -5821 | -5605 | |||
Financing Cash Flow Items | -99 | -69 | |||
Total Cash Dividends Paid | -4168 | -4168 | |||
Issuance (Retirement) of Stock, Net | -309 | -320 | |||
Issuance (Retirement) of Debt, Net | -1245 | -1048 | |||
Foreign Exchange Effects | 8 | 40 | |||
Net Change in Cash | 2638 | -3199 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
L'Oreal SA | Corporation | 9.3672 | 118227307 | 0 | 2023-01-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 7.3542 | 92820373 | -109952 | 2022-12-01 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.6227 | 33101922 | 275247 | 2023-04-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.1046 | 26563280 | 1278355 | 2022-12-31 | LOW |
Sanofi SA Employees | Corporation | 2.0112 | 25384441 | -502060 | 2023-01-31 | LOW |
Dodge & Cox | Investment Advisor/Hedge Fund | 1.9805 | 24996804 | -38447917 | 2022-12-31 | LOW |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 1.7093 | 21574287 | -49732 | 2023-04-30 | MED |
T. Rowe Price Associates, Inc. | Investment Advisor | 1.3742 | 17344626 | -233 | 2022-12-01 | LOW |
Fidelity International | Investment Advisor | 0.9794 | 12360920 | -275605 | 2023-03-31 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.9046 | 11416977 | -61760 | 2023-04-30 | LOW |
Mellon Investments Corporation | Investment Advisor/Hedge Fund | 0.8696 | 10976049 | 9625458 | 2022-11-30 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7484 | 9446072 | -3499 | 2023-04-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.687 | 8670792 | 69 | 2023-04-30 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 0.6778 | 8554174 | -47826 | 2023-04-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 0.6157 | 7770600 | 31042 | 2023-03-31 | LOW |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.576 | 7269728 | 20328 | 2023-04-30 | LOW |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.5352 | 6755031 | -165288 | 2023-03-31 | LOW |
BNP Paribas Asset Management France SAS | Investment Advisor/Hedge Fund | 0.5247 | 6622974 | 93156 | 2023-04-30 | LOW |
First Eagle Investment Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5245 | 6620194 | -1970 | 2023-03-31 | LOW |
Schroder Investment Management Ltd. (SIM) | Investment Advisor/Hedge Fund | 0.4129 | 5211829 | -127 | 2023-04-30 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group530K+
Traders
87K+
Active clients monthly
$46M+
Monthly investing volume
$31M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sanofi Company profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.Industry: | Pharmaceuticals (NEC) |
46 Avenue de la Grande Armée
PARIS
ILE-DE-FRANCE 75017
FR
Income Statement
- Annual
- Quarterly
News

Nvidia’s 5-year stock forecast: Will the chipmaker remain at record highs?
Nvidia has been the winner of the AI race, being the first chip-maker to hit a $1tn market cap. Will the growth continue?
07:46, 31 May 2023
Google stock forecast 2023-2025
What is the outlook for the tech giant, following a tumultuous 2022?
18:02, 30 May 2023
USD forecast: DXY slides in risk-off market sentiment
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
16:10, 24 May 2023
Oil price forecast: Will WTI and Brent regain momentum in 2023?
Discover the drivers behind Brent and WTI volatility and get insights from analyst predictions.
11:38, 22 May 2023
Weekly Roundup: Tech stocks lead the way
US stocks push higher as risk appetite surges despite the uncertainty
13:39, 19 May 2023
USD/JPY continues to build higher towards 138
USD/JPY advances towards the top of its ascending triangle as the US dollar moves higher
11:50, 17 May 2023
Gold price predictions for next 5 years: Will gold continue rising?
The yellow metal reached near record-highs, yet will it maintain the momentum and for how long?
07:50, 17 May 2023People also watch
Still looking for a broker you can trust?
Join the 530.000+ traders worldwide that chose to trade with Capital.com